Antibody-drug conjugates (ADCs) are transforming oncology with their ability to deliver potent cytotoxic agents directly to tumor cells, combining the targeting precision of monoclonal antibodies with ...

Underpinning successful ADC development is a robust, reproducible, and scalable process development strategy. From controlling impurities and optimizing conjugation yield to streamlining unit ...

Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary ...

WuXi XDC, a CRDMO, agreed to collaborate with Earendil Labs on WuXi XDC’s WuXiTecan-2 payload-linker technology platform. The partnership is aimed at accelerating the development of next-gen ADCs by ...

Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...

The 5th World ADC Summit South Korea (9-11 June 2026 | Seoul) is Asia's premier meeting dedicated to accelerating next-generation antibody drug conjugate (ADC) development. As part of the broader ...

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- WuXi XDC ("XDC"), a leading global CRDMO company dedicated to end-to-end bioconjugates services, announced that it received the Runner Up prize in the "Best ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...

Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to ...

TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...